A Phase II clinical trial demonstrated that combining the IDO pathway inhibitor indoximod with pembrolizumab was well-tolerated and yielded a 51% objective response rate, including a 20% complete response rate and a 70% disease control rate, suggesting significant antitumor efficacy in advanced melanoma, particularly in PD-L1-positive patients [143]. Here, IDO1 is linked to melanoma.